Plecanatide: Novel Approach for GI Disease
Synergy’s lead GC-C agonist, plecanatide, is in development for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).
Proprietary analog of a natural GI hormone
Plecanatide belongs to a new class of drugs, known as GC-C agonists, and works by mimicking the functions of uroguanylin, a natural human gastrointestinal hormone.
- Plecanatide is a 16-mer analog of the human hormone, uroguanylin
- Natural agonist of the guanylate cyclase-C (GC-C) receptor
- Single key amino acid change - plecanatide binding constant to human GC-C receptors is 8-fold higher than uroguanylin
- Oral, once-daily dosing
- Essentially non-systemic with excellent tolerability
- Targets GC-C receptors in the GI tract
- Models normal physiology
Potential to be "best in class"
Ongoing clinical trials suggest that plecanatide has the potential to be “best in class”, providing an ideal combination of efficacy, safety, minimal side effects and once-daily oral dosing.
Learn more about the clinical trials
Learn more about the science behind GC-C agonists
Download the plecanatide fact sheet